<?xml version='1.0' encoding='utf-8'?>
<document id="31674039"><sentence text="Dasotraline as a selective cytochrome 2B6 inhibitor for reaction phenotyping."><entity charOffset="0-11" id="DDI-PubMed.31674039.s1.e0" text="Dasotraline" /></sentence><sentence text="Reaction phenotyping using human liver microsomes or hepatocytes with chemical inhibitors is one of the most commonly applied methods to assess the fraction metabolized (fm ) of drug candidates by enzymes" /><sentence text=" The fm information is critical to understanding the risk of victim drug-drug interactions in the clinic" /><sentence text=" Inhibitor selectivity is essential in order to generate reliable data and irreversible inhibitors are often preferred over reversible inhibitors to minimize the impact of inhibitor depletion" /><sentence text=" Although many selective cytochrome P450 (CYP) inhibitors are available, the identification of selective CYP2B6 inhibitors has been challenging due to cross inhibition to the other enzymes" /><sentence text=" In this study, dasotraline was evaluated as a selective inactivator of CYP2B6 under reaction phenotyping conditions with human hepatocytes"><entity charOffset="16-27" id="DDI-PubMed.31674039.s6.e0" text="dasotraline" /></sentence><sentence text=" The results show that dasotraline is a very selective inactivator for CYP2B6 with minimal inhibition to other enzymes"><entity charOffset="23-34" id="DDI-PubMed.31674039.s7.e0" text="dasotraline" /></sentence><sentence text=" A concentration of 0" /><sentence text="1 μM dasotraline is recommended for reaction phenotyping with a hepatocyte cell density of 0"><entity charOffset="0-16" id="DDI-PubMed.31674039.s9.e0" text="1 μM dasotraline" /></sentence><sentence text="5 million cells/ml or 0" /><sentence text="5 μM for 2 million cells/ml, when using a 15 minute preincubation, as well as the protocol of inactivator removal before the addition of substrates" /><sentence text="" /></document>